Live Breaking News & Updates on Amgen Global Medical Organization

Share this article
Share this article
EMERYVILLE, Calif., April 13, 2021 /PRNewswire/ Kyverna Therapeutics ( Kyverna ), a cell therapy company engineering a new class of therapies for serious autoimmune diseases, today announced the appointment of James Chung, M.D., Ph.D., as the Company s first Chief Medical Officer. Dr. Chung brings extensive biopharmaceutical industry experience working across the entire drug development process focused on autoimmune diseases and has dedicated a significant part of his career working in translational medicine and early clinical development. By leading the Company s Clinical Development organization, he will contribute to Kyverna s transition to a clinical-stage company.
James Chung, M.D., Ph.D., Chief Medical Officer, Kyverna Therapeutics ....

Ignacio Sanz , Eugenec Butcher , Christophe Benoist , Global Medical Organization , Division Of Rheumatology , Global Development Leader For Enbrel , Emory University , Global Development , Lowance Center , Early Development Inflammation Therapeutic Area Head , Harvard Medical School , Sciences Early Development , Clinical Sciences At Pfizer , Biology At Harvard College , University Of Pennsylvania , Amgen Global Medical Organization , Stanford University , Executive Medical Director , Global Development Leader , Early Development , Associate Director , Clinical Sciences , Early Clinical Leader , Internal Medicine , Scientific Advisors , Morton Grove Rasmussen Chair ,